



مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

CETUXimab (every 2 weeks)



* C T X - 0 0 0 0 0 - 0 2 - C N - G I *



Ministry of Health

Name:

File #:

Ht (cm):

Nationality:

Civil ID:

Wt (Kg):

Gender/Age:

DOB:

BSA (m²):

Indication(s): Neoadjuvant Adjuvant Palliative

Central line: Available NA

Allergies: NKA Yes, specify; _____

Parameters: Initiate treatment only if ANC ≥ 1500; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min.

Standard Protocol:

| DRUG | DOSE | ADMINISTRATION | DAYS |
|--|-----------------------|--|------|
| CETUXimab | 500 mg/m ² | IV undiluted over 2 hr. Then, flush the IV line with 50 mL NS at end of infusion. | D1 |
| To be repeated every 2 weeks until disease progression or intolerable toxicity. | | | |

Special instructions: Keep the patient for 1 hr observation period after completion of the 1st and 2nd cycle of CETUXimab infusion.

Treatment Description:

| Cycle | Date | CETUXimab | Physician | Consultant |
|-------|------|-----------|-----------|------------|
| C# __ | | | | |
| C# __ | | | | |
| C# __ | | | | |
| C# __ | | | | |
| C# __ | | | | |
| C# __ | | | | |

Important Notes:

Reported grade 3/4 toxicities: None Hematological Non-Hematological

If yes; Did it indicate hospitalization? Yes No

Did it indicate chemo-delay for ≥ 7 days? Yes No

Did it indicate dose reduction? Yes No

Did it indicate G-CSF support? Yes No